BR112022020716A2 - Anticorpos anti-tumor associados ao antígeno e usos dos mesmos - Google Patents
Anticorpos anti-tumor associados ao antígeno e usos dos mesmosInfo
- Publication number
- BR112022020716A2 BR112022020716A2 BR112022020716A BR112022020716A BR112022020716A2 BR 112022020716 A2 BR112022020716 A2 BR 112022020716A2 BR 112022020716 A BR112022020716 A BR 112022020716A BR 112022020716 A BR112022020716 A BR 112022020716A BR 112022020716 A2 BR112022020716 A2 BR 112022020716A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- antigen
- tumor antibodies
- antibodies associated
- tumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021215P | 2020-05-07 | 2020-05-07 | |
| US202062706131P | 2020-08-03 | 2020-08-03 | |
| US202063198420P | 2020-10-16 | 2020-10-16 | |
| US202063131394P | 2020-12-29 | 2020-12-29 | |
| PCT/US2021/031055 WO2021226321A2 (en) | 2020-05-07 | 2021-05-06 | Anti-tumor associated antigen antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020716A2 true BR112022020716A2 (pt) | 2022-11-29 |
Family
ID=78468388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020716A BR112022020716A2 (pt) | 2020-05-07 | 2021-05-06 | Anticorpos anti-tumor associados ao antígeno e usos dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230220107A1 (https=) |
| EP (1) | EP4146702A4 (https=) |
| JP (1) | JP7821121B2 (https=) |
| KR (1) | KR20230007452A (https=) |
| CN (1) | CN115515981A (https=) |
| AU (1) | AU2021267893A1 (https=) |
| BR (1) | BR112022020716A2 (https=) |
| CA (1) | CA3173176A1 (https=) |
| IL (1) | IL297955A (https=) |
| MX (1) | MX2022013920A (https=) |
| WO (1) | WO2021226321A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| WO2022197949A2 (en) | 2021-03-17 | 2022-09-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| TW202426058A (zh) * | 2022-10-18 | 2024-07-01 | 加拿大商酵活英屬哥倫比亞有限公司 | 靶向磷脂醯肌醇蛋白聚糖－３之抗體－藥物結合物及使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| ME02345B (me) * | 2007-07-17 | 2016-08-31 | Squibb & Sons Llc | MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3 |
| EP2699603B1 (en) * | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| WO2015179658A2 (en) * | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TW201713700A (zh) * | 2015-05-27 | 2017-04-16 | 台灣泰福生技股份有限公司 | 抗ｇｌｙｐｉｃａｎ-３抗體及其用於診斷及治療癌症之用途 |
| US11072666B2 (en) * | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| US11767362B1 (en) * | 2016-03-15 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
| WO2017162587A1 (en) * | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| US11299708B2 (en) * | 2016-05-12 | 2022-04-12 | Adicet Bio, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
| UA128383C2 (uk) * | 2016-12-07 | 2024-07-03 | Дженентек, Інк. | Антитіло до тау-білка та спосіб його застосування |
| EP3615574A4 (en) * | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| WO2019059411A1 (en) * | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
| AR114112A1 (es) * | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| CN111040036B (zh) * | 2018-10-12 | 2023-10-20 | 上海卡智生物技术有限公司 | 抗gpc3单克隆抗体、由其修饰的免疫效应细胞及其应用 |
-
2021
- 2021-05-06 MX MX2022013920A patent/MX2022013920A/es unknown
- 2021-05-06 KR KR1020227041924A patent/KR20230007452A/ko active Pending
- 2021-05-06 JP JP2022567223A patent/JP7821121B2/ja active Active
- 2021-05-06 EP EP21800926.4A patent/EP4146702A4/en active Pending
- 2021-05-06 CA CA3173176A patent/CA3173176A1/en active Pending
- 2021-05-06 IL IL297955A patent/IL297955A/en unknown
- 2021-05-06 BR BR112022020716A patent/BR112022020716A2/pt unknown
- 2021-05-06 CN CN202180032994.3A patent/CN115515981A/zh active Pending
- 2021-05-06 AU AU2021267893A patent/AU2021267893A1/en active Pending
- 2021-05-06 US US17/997,755 patent/US20230220107A1/en active Pending
- 2021-05-06 WO PCT/US2021/031055 patent/WO2021226321A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021267893A1 (en) | 2022-11-03 |
| US20230220107A1 (en) | 2023-07-13 |
| JP7821121B2 (ja) | 2026-02-26 |
| MX2022013920A (es) | 2022-11-30 |
| WO2021226321A2 (en) | 2021-11-11 |
| IL297955A (en) | 2023-01-01 |
| EP4146702A2 (en) | 2023-03-15 |
| CN115515981A (zh) | 2022-12-23 |
| WO2021226321A3 (en) | 2021-12-16 |
| CA3173176A1 (en) | 2021-11-11 |
| JP2023525991A (ja) | 2023-06-20 |
| EP4146702A4 (en) | 2024-07-10 |
| KR20230007452A (ko) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000370A (es) | Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos | |
| UY39416A (es) | Moléculas de direccionamiento inmunes multiespecíficas y usos de estas | |
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| CO2020014575A2 (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos | |
| CL2019002566A1 (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| JOP20210297A1 (ar) | مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية | |
| CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
| BR112022020716A2 (pt) | Anticorpos anti-tumor associados ao antígeno e usos dos mesmos | |
| AR106570A1 (es) | Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| BR112022002579A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
| BR112019000436A2 (pt) | anticorpos anti-pd-1, método de produção e método de uso dos mesmos | |
| MX2020011914A (es) | Anticuerpos anti-dll3 y usos de los mismos. | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| BR112023002301A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
| UY38520A (es) | Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos | |
| AR101735A1 (es) | Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro) | |
| BR112022020410A2 (pt) | Anticorpos anti-phf-tau e usos dos mesmos | |
| BR112023020303A2 (pt) | Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos | |
| BR112022026341A2 (pt) | Anticorpos e métodos para o tratamento de doenças associadas à claudina | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| BR112023019546A2 (pt) | Anticorpos anti-tau e usos dos mesmos | |
| EA202192008A1 (ru) | Lilrb3-связывающие молекулы и варианты их применения | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
| BR112022004998A2 (pt) | Anticorpos anti-tigit e usos dos mesmos |